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Abstract 
Background: A routine audit revealed that the analytical method used to measure digoxin 
concentrations by our State-wide pathology provider in 2009 was underestimating digoxin 
concentrations by 10%.  The assay was recalibrated by the manufacturer in 2010 but clinical 
outcomes of the underestimation were never measured. This is a pilot study to describe the 
prescribing behaviour around out of range digoxin concentrations, and to assess if miscalibrated 
digoxin immunoassays contribute to clinically relevant effects as measured by inappropriate 
alterations in digoxin doses. 
Methods: 30,000 digoxin concentrations across the State Hospital system were obtained in two 
periods before and after recalibration of the digoxin assay.  Digoxin concentration means were 
calculated and compared and were statistically significantly different. Subsequently, a single-
centred retrospective review of 50 randomly chosen charts was undertaken to study the clinical 
implications of the underestimated concentrations.  
Results: Mean digoxin concentrations for 2009 and 2011 were significantly different by 8.8% 
(CI 7.0%-10.6%). After recalculating 2009 concentrations to their ‘corrected’ values, there was 
a 16% increase in the number of concentrations within the range when compared to 2011 
(41.48% vs 48.04%). However, overall this did not cause unnecessary dose changes in patients 
that were ‘borderline’ or outside of the therapeutic range, when compared to controls (P = 0.10). 
The majority of decisions were based on the clinical impression rather than concentration alone 
(85.1% vs. 14.9%), even when the concentration was outside of the ‘therapeutic range’.  
Conclusion: Although, recalculating  digoxin concentrations measured during 2009 to their 
‘corrected’ values produced a significant change in concentration and values inside and outside 
of the range, this does not appear to have had an influence on patient treatment. Rather, 
clinicians tended to use the clinical impression to dose digoxin.  
Key Words: digoxin, therapeutic drug monitoring, serum concentrations, prescribing 
behaviour, miscalibrated assay   
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Introduction: 
Digoxin is still used in the treatment of atrial fibrillation (AF) and heart failure but requires 
therapeutic drug monitoring (TDM) due to its narrow therapeutic range (0.8-2.0 µg/L for AF).1, 2 
TDM requires a complex set of people and system resources – pre validation and calibration, 
analytical aspects, post validation, reporting and interpretation; a set of factors not commonly 
found all together in one laboratory.  
There is evidence to show that measured plasma digoxin concentrations may vary by a clinically 
significant amount as a result of the use of different methods and/or analysers and from 
interference from digoxin-like immunoreactive substances (DLIS).3-7 This can lead to 
inappropriate digoxin dosing which can potentially lead to serious problems for patients’ 
health.3, 4  
During an external quality assurance program in 2010, the Beckman Coulter plasma and serum 
turbidimetric inhibition digoxin immunoassay used by Pathology Queensland in 2009 was 
found to be approximately 10% lower than the true value (personal communication Jill Tate, 
senior scientist Chemical Pathology, Pathology Queensland). As a result, the manufacturer re-
standardised the method later in 2010 against a higher order reference method; however, the 
clinical effects of this recalibration were never quantified. For the Beckman Coulter digoxin 
assay, the laboratory has a between-run precision of 5% coefficient of variation (CV) at a 
concentration of 2.0 µg/L. Hence, values of 1.8-2.2 µg/L are considered equivalent and within 
the allowable limits of performance of 10% CV. An additional positive bias of 10% however, 
will contribute to an extra 0.2 µg/L. This may elevate a value of 2.0 µg/L to 2.4 µg/L (toxic 
range) or may lower it to 1.6 µg/L (within the therapeutic range) if there was a negative bias. 
This would seem clinically significant as higher concentrations of digoxin have been associated 
with an increase in toxicity.8, 9  
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The present study considered whether clinicians made decisions based on the patient’s clinical 
situation or impression and not solely on measured digoxin concentrations. If clinicians based 
their decisions solely on the clinical impression, then any discordance between measured 
digoxin concentrations may not have had a significant clinical impact. 
A literature review concluded that there are no data on the clinical outcomes of either biased or 
imprecise plasma digoxin concentration measurements regardless of the cause; whether from 
variability between analysers or interference from DLIS.4-7 However, a New Zealand study has 
shown that clinicians were more inclined to dose patients based on their clinical situation when 
serum digoxin concentrations were low, while high digoxin concentrations were deemed to 
represent toxicity regardless of the patient’s clinical impression.10 This is consistent with 
research showing that higher digoxin concentrations may correlate with digoxin toxicity.8, 9 
Nonetheless, data on current digoxin prescribing in Australia are still lacking; and it has been 
suggested by the literature that future method comparison studies would benefit from protocols 
that include the effect on clinical decision-making, not solely measures of analytical 
performance in isolation.4 
Consequently, this is a pilot study to describe the prescribing behaviour around out of range 
digoxin concentrations, and to assess if miscalibrated digoxin immunoassays contribute to 
clinically relevant effects. 
Thus, the aims of this study were to firstly ascertain if recalculation of  data collected during 
2009 to their ‘corrected’ values altered the number of concentrations within the therapeutic 
range for that year. Secondly, to investigate if unnecessary alterations in digoxin doses occurred 
after recalculating the 2009 data to the ‘corrected’ concentrations. Lastly, whether clinicians 
dosed digoxin purely on measured concentrations or their clinical impression (as judged by 
blinded assessment).  
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Materials and Methods: 
Determining the difference between pre and post calibrated concentrations 
To define the difference in average digoxin concentrations pre (2009) and post calibration 
(2011), de-identified Pathology Queensland Statewide data for digoxin concentrations were 
obtained for the two time periods. The mean digoxin concentrations for both years were 
calculated and a two-sample student T-test was performed for comparison. All concentrations 
were analysed, including first measurements. 
Concentrations from 2009 were then corrected by the percentage of the mean difference found 
between 2009 and 2011 and the number of concentrations within the range pre and post 
recalculation were compared using Pearson’s chi-squared analysis. The therapeutic range used 
was the standard Pathology Queensland range of 0.8-2.0 µg/L which is the accepted range for 
the treatment of AF.1, 11  
Clinical implications of underestimating digoxin concentrations and clinical 
prescribing behaviour of digoxin 
The second and third aims of this study examined the clinical implications of underestimating 
digoxin concentrations in 2009. To achieve this, a single-centre retrospective chart review by a 
clinical expert was devised. Prior ethical approval from the Research and Ethics Committees of 
Queensland Health Metro South, Pathology Queensland Governance and The University of 
Queensland was obtained. 
Patient selection for clinical relevance section:  
As this was a pilot study, a smaller sample was chosen for an in depth chart review. 50 charts 
from the Princess Alexandra Hospital (PAH) of patients who had borderline digoxin 
concentrations (0.8 or 2.0 µg/L) or were outside of the range (< 0.8 or >2.0 µg/L) during a 6 
month period in 2009 were randomly selected by systematic sampling using an equal-
probability method. Of these 50 charts, 25 charts had borderline digoxin concentrations with 7 
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charts in the >2.0 µg/L group and 18 charts in the < 0.8 µg/L group. The other 25 charts had 
digoxin concentrations outside of the range with 12 charts in the >2.0 µg/L group and 13 charts 
in the < 0.8 µg/L group. Ten additional charts of patients who had digoxin concentrations within 
the range were also randomly selected using the same methodology. These ten charts were used 
as control samples as it was assumed that no changes in dosing were made if concentrations 
were within the range.   
Thus, including controls, 60 charts in total were examined. Charts were excluded if insufficient 
clinical data were available to make a judgement on whether appropriate management was 
undertaken; or if the patient was on digoxin for indications other than AF. Patients who were on 
digoxin for both AF and congestive heart failure were included. 
All concentrations were measured using the Beckman DxC (Beckman Coulter, Brea, CA) 
analyser at the PAH, Queensland, Australia. Patient data collected included age, sex, sampling 
and dosing times, digoxin concentrations and doses, serum creatinine, serum potassium, weight, 
co-morbidities, number of medications, signs of under or overdosing and whether patients were 
concurrently on other anti-arrhythmic drugs. Sampling and dosing times were recorded to 
ensure digoxin concentrations were sampled at the appropriate times (Table 1). Although 
creatinine clearance estimations would have been a better estimate of renal function, serum 
creatinine was used due to the inability to locate patients’ weights in more than half of the 
charts.  The list of recorded data is further detailed in Table 1.  
Study end-points:  
Clinical implications of underestimating digoxin concentrations  
The second aim of this study was to assess whether unnecessary alterations in digoxin doses 
would have occurred after recalculating the  data collected in 2009 to the corrected 
concentrations. Thus, clinical charts were examined to assess whether appropriate decisions 
were made based on the original concentrations prior to instrument recalibration in 2009. 
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Decisions for that particular concentration were classified as either: appropriate or 
inappropriate.  
An appropriate decision was defined as a change in digoxin dose consistent with the corrected 
concentration and was the variable of interest. For example, if the corrected concentration was 
below the range and an increase in dose was recorded, this would be an appropriate decision. 
However, if the corrected concentration fell below the range and no change in dose was 
recorded, this would be defined as an inappropriate decision for the purpose of this study. Here, 
the clinical stability of the patient was not taken into account; only if the corrected concentration 
warranted a change in dose in the view of the independent expert reviewer.  
Concentrations that were borderline and outside the range were compared to concentrations that 
were within the range (control) using Fisher’s exact tests. Subgroup analysis was also 
performed comparing whether the difference between appropriate decisions varied between the 
< 0.8, 0.8, 2.0 and > 2.0 µg/L groups.   
Clinical prescribing behaviour for digoxin 
The third aim was to elucidate whether clinicians tended to dose digoxin based on the measured 
digoxin concentration or based on a patient’s overall clinical impression. This was of interest as 
there are currently no digoxin prescribing guidelines available at the PAH. Actions for each 
digoxin concentration selected were classified into 2 groups: actions based on either 
concentration or clinical impression. It was agreed that if a clinician used both the patient’s 
concentration and the clinical impression of the patient, this would be classified under the 
clinical impression group. This is because it was difficult to ascertain whether concentrations 
that were out of the range happened coincidently when clinicians altered the dose of patients. 
The definitions for the two groups are as follows: 
Concentration only: Dose changed after concentration selected was out of the therapeutic range 
without any signs of clinical instability.  
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Clinical impression : Dose changed or unchanged based on patient’s clinical stability regardless 
of therapeutic range.  
Criteria for toxicity or underdosing are defined in Table 1. Subgroup analysis was performed 
for < 0.8, 0.8, 2.0 and > 2.0 µg/L groups.  Other variables that may have impacted on the 
clinician’s decision making were also analysed using Fisher’s exact test. This included being on 
other anti-arrhythmic drugs, patient’s weight, high serum creatinine, potassium concentration, 
gender, age, appropriate sampling times for dosing (at steady state, or greater than 6 hours), 
polypharmacy, and other co-morbidities.  
Statistical Analysis Summary:  
Univariate statistical analysis was performed using Chi-square tests for categorical variables and 
student’s T-test for normally distributed continuous variables. Fisher’s exact test was used for 
paired data for aims two and three due to smaller sample sizes. A two-sided P value of < 0.05 
was considered to indicate statistical significance. All calculations were performed using 
MedCalc for Windows, version 12.7.7 (MedCalc Software, Ostend, Belgium).  
Results: 
Difference between pre and post recalculated digoxin concentrations 
In 2009, there were 15,833 measured digoxin concentrations reported from Pathology 
Queensland laboratories State-wide with a mean concentration of 0.81 ± 0.70 µg/L, while in 
2011 there were 15,816 measured concentrations with a mean concentration of 0.88 ± 0.72 
µg/L. Student’s T test showed a significant difference of approximately 8.8% (CI 7.0%-10.6%) 
between the 2009 and 2011 concentrations.  
Concentrations in 2009 were then retrospectively recalculated and increased by a factor of 8.8% 
to reflect the underestimation of the pre 2010 Beckman method. There was no clinically 
significant difference when recalculating the concentrations by either 8.8% or the proposed 10% 
(P = 1.00). The proportion of digoxin measurements which were within the range was found to 
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differ significantly between the 2009 pre (41.48% within the range) and post (48.04% within the 
range) recalculated measurements (6.19% difference, CI 5.10%-7.29%, P < 0.0001). The 
difference between the number of digoxin concentrations that were within the range for post 
recalculated 2009 digoxin concentrations and 2011 digoxin concentrations was not statistically 
significant (48.04% vs. 46.9%, P = 0.25). This suggests that recalculated concentrations from 
2009 correlated with recalibrated digoxin concentrations from 2011. 
Clinical implications of underestimating digoxin concentrations  
57 charts in total were examined. Three charts were excluded from the borderline group 
according to the exclusion criteria. The final number of charts examined per group is 
summarised in Table 2.  
Of the 47 charts examined of patients with concentrations measured in 2009 that were 
borderline or out of the range, 34 (72.34%) charts had appropriate decisions. There was no 
significant difference when compared to the controls which had 100% appropriate decisions (P 
= 0.10). Subgroup analysis was also performed comparing whether the difference between 
appropriate decisions varied between the < 0.8, 0.8, 2.0 and > 2.0 µg/L groups. There was a 
significant difference between the < 0.8 µg/L group and the other three groups (0.8 µg/L: 
P=0.0003, 2.0 µg/L: P=0.016, > 2.0 µg/L: P=0.009). This was because post recalculated 
concentrations that were < 0.8 µg/L were still below the range but no increase in doses were 
noted in the majority of these patients. There were no significant changes between the other 
groups.  
Clinical prescribing behaviour of digoxin 
Of the 47 charts examined of patients with concentrations that were borderline or out of the 
range, the majority of decisions were based on clinical impression (85.1%) as opposed to 
concentration alone (14.9%). However, this was not equal in all groups. Decisions made by 
concentration only were significant for digoxin concentrations > 2.0 µg/L compared to other 
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groups (< 0.8 µg/L: P=0.04, 0.8 µg/L: P=0.02) but not significantly different from the 2.0 µg/L 
group (P=0.63).  
There appeared to be a trend for clinical impression decision making for patients that were on 
other anti-arrhythmic drugs (OR 3.06, 95% CI 0.53-17.66), however this proved to be not 
significant (P=0.24). Other variables also did not appear to significantly impact on whether 
clinicians based their decision on the clinical impression or the digoxin concentration as 
demonstrated in Table 3. The impact of serum potassium was not analysed as all samples 
recorded were within the appropriate reference range.1 
Discussion:  
Difference between pre and post recalculated concentrations  
A significant number of pre recalculated concentrations in 2009 were within the range post 
recalculation. This validates previous concerns about the clinical significance of 
underestimating the  data collected in 2009.  Although the mean difference between  
concentrations measured 2009 and 2011was marginally less than expected, this proved not to be 
statistically significant. Thus, recalculating the 2009 data by 8.8% or the expected 10% would 
not have affected the results. 
Clinical implications of underestimating digoxin concentrations  
Overall, recalibration of the digoxin assay did not significantly clinically impact on unnecessary 
decision making. However, there was a significant difference between the < 0.8 µg/L group and 
the other three groups. This was because post recalculation, concentrations that were < 0.8 µg/L 
were still below the range but no increases in doses were noted in the majority of them. 
Clinicians are generally satisfied with a concentration that is below the therapeutic range as long 
as the patient is clinically stable (as discussed below). One clinician wrote that, “There was no 
need for repeat digoxin concentrations as the aim for treatment is rate control and the 
concentrations do not need to be therapeutic”. In another chart of a patient with concomitant 
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congestive heart failure the clinician wrote that “it was appropriate to aim for low 
concentrations in congestive heart failure”; a clinical practice which is in fact supported by the 
literature but for which there is no quoted therapeutic range.12-14 
Clinical prescribing behaviour of digoxin 
The vast majority of decisions when prescribing digoxin were based on the clinical impression 
as opposed to concentration alone. This was particularly true with concentrations that were 
below the therapeutic range even when concentrations were very low (0.3 µg/L). However 
changes based on concentrations were significantly higher in the > 2.0 µg/L group as clinicians 
appear to be more cautious about toxicity at concentrations above the range. In fact, in charts of 
two patients who were borderline high (2.0 µg/L), clinicians specifically noted that although the 
patients were rate controlled, the dose was reduced because the digoxin concentration was close 
to the upper limit. A possible contributing factor to this finding is the fact that Pathology 
Queensland has assigned a digoxin concentration of > 2.0 µg/L as a critical result that must be 
verbally given to the treating team of the patient, thus, giving the treating clinician an additional 
prompt for action.  Nonetheless, although digoxin concentrations may not always correlate well 
to the clinical impression10, this trend in dosing is probably associated with best clinical 
practice. This is because digoxin toxicity could potentially be fatal and the clinical benefits of 
higher concentrations are questionable.10 These findings of clinicians having a greater reliance 
on laboratory results when digoxin concentrations are at or above the upper limit of the 
therapeutic range demonstrate similarities in prescribing practice between Australia and New 
Zealand.10 
It was also noted that there was a trend towards more decisions being based on the clinical 
impression rather than on digoxin concentrations for patients who were on other anti-arrhythmic 
drugs; however, this was not significant. This trend may be explained by the fact that doses of 
other co-administered anti-arrhythmic drugs were changed concomitantly, while the digoxin 
dose was unaltered regardless of the concentration measured. Other variables did not appear to 
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have any significant impact on whether clinicians based their decisions on the clinical picture, 
clinical impression, or concentration (Table 3).   
It can thus be concluded that clinicians generally dosed digoxin based on a patient’s clinical 
impression when concentrations were < 0.8 µg/L. Conversely, they tended to use both the 
patient’s clinical impression and digoxin concentrations for concentrations > 2.0 µg/L. Overall 
however, the majority of clinicians were treating the patient and not the concentration on a test 
report, even when the concentrations were well outside the ‘therapeutic range’. Whether the 
heavy reliance on the clinical impression is a result, at least in part, of a clinician’s awareness of 
the limitations in assay method accuracy or due to influence from local prescribing culture 
needs to be further investigated. Additionally, it can be implied that perhaps the current 
prescribing trends may be adequate as improved assay accuracy and performance could possibly 
result in the increased reliance on TDM.  
The fact that clinicians were treating ‘the patient and not the concentration,’ is a reassuring 
outcome. It suggests that although biases in digoxin assay methods are important to be aware of, 
inappropriate changes in dosing are unlikely to occur. In particular, increases in the number of 
digoxin toxicities are unlikely to occur because although clinicians generally dosed the patient 
according to the clinical impression when digoxin concentrations were low or within the range, 
they were guided more emphatically by concentrations when above the range. Given the use of 
low digoxin concentrations to good effect clinically, perhaps the lower limit of the current 
therapeutic range (0.8 µg/L) needs to be re-evaluated. 
Lastly, this pilot study demonstrates current digoxin prescribing trends in a large Australian 
tertiary hospital and the clinical use of digoxin concentrations. This could guide future studies 
containing protocols that include the effects on clinical decision-making from discordant drug 
concentration results from recalibration or altering methods. Furthermore, the study protocol 
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could potentially be applied to other drugs that require TDM due to their narrow therapeutic 
ranges such as lithium, cyclosporin and tacrolimus. 
Study limitations 
Some of the limitations of the study relates to its design. Being a retrospective chart review, it 
can only be assumed from what was written in the charts as to a clinician’s actual thought and 
practice processes. However, the text was examined by the clinical supervisor in a blinded 
manner for validation. It is also acknowledged that the smaller sample size means a lower 
powered study and a higher likelihood for type one and type two errors; thus increasing the risk 
of spurious results. In addition, analysing paired controls or subgroups in smaller sample sizes 
causes a further loss in power. This however, is inevitable and can only be addressed by 
increasing the sample size of similar studies in the future.  
Conclusion 
Although it has been demonstrated that recalculating  digoxin concentrations measured in 2009 
to their ‘corrected’ values produced a significant change in concentrations and values ‘inside’ 
and ‘outside’ of the therapeutic range, this does not appear to have had an influence on patient 
treatment; at least in the eight to ten percent bias range. Our chart analysis study has shown that 
the majority of clinicians used their clinical impression to dose digoxin, rather than 
concentration for most patients, with greater reliance on the concentration at or above the upper 
limit of the therapeutic range. Whilst unexpected, it is a clinically useful finding and consistent 
with TDM teaching i.e. that a result be used in the total context of the patient’s clinical 
impression when prescribing a dose of a drug. This work and the study design are likely to be 
helpful for laboratories when planning research to assess clinical impact when a new instrument 
or methodology is introduced in the laboratory. 
Acknowledgements  
We acknowledge my colleague Benny Tu for his assistance in the statistical analysis of this 
AC
CE
PT
ED
                                                                                                                                      Page 14 of 15 
 
study. 
AC
CE
PT
ED
                                                                                                                                      Page 15 of 15 
 
 
References 
 
1. Ehle M, Patel C, Giugliano R. Digoxin: Clinical Highlights: A review of digoxin 
and it’s use in contemporary medicine. Crit Pathw Cardiol. 2011; 10: 93-98. 
2. Opie L. Digitalis, yesterday and today, but not forever. Circ Cardiovasc Qual 
Outcomes. 2013; 6: 511-513.   
3. Norris R, Martin J, Thompson E, et al. Current status of therapeutic drug 
monitoring in Australia and New Zealand: A need for improved assay 
evaluation, best practice guidelines, and professional development. Ther Drug 
Monit. 2010; 32: 615-623.  
4. Rogers N, Jones T, Morris R. Frequently discordant results from therapeutic 
drug monitoring for digoxin: clinical confusion for the prescriber. Intern Med J. 
2010; 40: 52-56.  
5. Jones T, Morris R. Discordant results from "Real-World" patient samples 
assayed for digoxin. Ann Pharmacother. 2008; 42: 1791-1803.  
6. Cobo A, Martin-Suarez A, Calvo M, et al. Clinical repercussions of analytical 
interferences due to aldosterone antagonists in digoxin immunoassays: An 
assessment. Ther Drug Monit. 2010; 32: 169-176.  
7. Morris R, Jones T, Goldsworthy S, et al. Suspected DLIS interference in the 
dimension DGNA digoxin assay method and the clinical application of the 
revised digoxin target range. Ther Drug Monit. 2006; 28: 454-457.  
8. Smith TW, Haber E. Digoxin Intoxication: the relationship of clinical 
presentation to serum digoxin concentration. J Clin Invest. 1970; 49: 2377–
2386.  
9. Beller GA, Smith TW, Abelmann WH, et al. Digitalis intoxication. A 
prospective clinical study with serum level correlations. N Engl J Med. 1971; 
284: 989–997.  
10. Sidwell A, Barclay M, Begg E, et al. Digoxin therapeutic drug monitoring: an 
audit and review. N Z Med J. 2003; 116: 1-6.  
11. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited [Updated 
Mar 2013; cited 15 Aug 2013]. Available from: 
http://online.tg.org.au.ezproxy.library.uq.edu.au/ip/desktop/index.htm 
12. The Digitalis Investigation Group. The effect of digoxin on mortality and 
morbidity in patients with heart failure. N Engl J Med. 1997; 336: 525-533.  
13. Ahmed A, Gambassi G, Weaver M, et al. Effects of discontinuation of digoxin 
versus continuation at low serum digoxin concentrations in chronic heart failure. 
Am J Cardiol. 2007; 100: 280–284. 
14. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin 
concentration and outcomes in patients with heart failure. JAMA. 2003; 289:  
871–878. 
AC
CE
PT
ED
Tables 
 
Table 1. Patient data collected. 
 
Criteria 
Signs of toxicity  Bradycardia (PR: <60 BPM or a drop in baseline >30 BPM).1 PR 
was used as an objective criterion and was consistently recorded 
in the charts. ECG changes reflecting digoxin toxicity were not 
used due to the variable availability within charts.1 
Signs of 
underdosing 
Tachycardia (PR: >100 BPM) or uncontrolled AF on ECG if 
available.1 
Anti-arrhythmics Other drugs used for controlling rate and rhythm in AF: atenolol, 
metoprolol, diltiazem, verapamil, amiodarone and flecainide.11 
Appropriate 
sampling time  
Trough sample measured at least 6 hours after a dose to allow for 
distribution.1 
Creatinine Normal range for Males: 64-108 µmol/L and Females: 46-99 
µmol/L1 
Co-morbidities IHD, CHF, HTN, Hypercholesterolaemia, T2DM, CVA, COPD, 
GORD, OA, CKD 
Polypharmacy Patients on ≥ 5 medications.12 
 
PR, pulse rate; ECG, electrocardiogram; AF, atrial fibrillation; IHD, ischaemic heart disease; CHF, congestive heart 
failure; HTN, hypertension,;T2DM, type 2 diabetes mellitus; CVA, cerebrovascular accident; COPD, chronic obstructive 
pulmonary disease; GORD, gastro-oesophageal reflux disease; OA, osteoarthritis; CKD, chronic kidney disease; BPM, 
beats per minute AC
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 Table 2. Summary of the final number of charts examined per group 
 
Group (µg/L) Number of charts % 
< 0.8 13 23 
0.8 17 30 
0.9-1.9 (Controls) 10 17 
2.0 5 9 
> 2.0 12 21 
Total 57 100 
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 Table 3. Significance of other variables on clinical decision making 
 
Other variables that may affect “clinical 
vs. concentration” groups 
OR (95% CI) P-values  
Anti-arrhythmic drugs  3.06 (0.53-17.66) 0.25 
Creatinine     0.61 (0.12-3.11) 0.69 
Patient’s weight † 0.31 
Gender (male vs. female) 0.75 (0.15-3.80) 1.00 
Age † 0.84 
Appropriate sampling times 0.80 (0.08-8.19) 1.00 
Poly-pharmacy 0.30 (0.02-5.81) 0.57 
Co-morbidities: 
IHD 
CHF 
HTN 
Hypercholesterolaemia 
T2DM 
CVA 
COPD 
GORD 
OA 
CKD 
 
0.61 (0.12-3.11) 
1.85 (0.09-38.11) 
1.63 (0.32-8.25) 
0.72 (0.14-3.67) 
5.16 (0.27-98.41) 
1.27 (0.13-12.30) 
4.52 (0.24-86.71) 
0.15 (0.01-2.80) 
0.67 (0.06-7.03) 
5.85 (0.31-110.91) 
 
0.69 
1.00 
0.69 
0.69 
0.32 
1.00 
0.32 
0.28 
0.57 
0.18 
 
 
† OR not applicable as T-test was performed 
 
IHD, ischaemic heart disease; CHF, congestive heart failure; HTN, hypertension,;T2DM, type 2 diabetes mellitus; CVA, 
cerebrovascular accident; COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reflux disease; 
OA, osteoarthritis; CKD, chronic kidney disease 
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